Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Plexium compound shows the promise of BRD4 degradation for prostate cancer

April 20, 2022

TLR2/6 agonist AXA-042 shows antitumor activity and tolerability in vivo

April 20, 2022

IKZF2 degrader PLX-4107 shows promise as cancer immunotherapeutic

April 19, 2022

FGFR2-selective inhibitor CGT-0292 shows promise for treating hyperphosphatemia

April 13, 2022

Peptidomimetic TMPRSS2 inhibitor shows prophylactic and therapeutic activity against SARS-CoV-2 VOCs

April 7, 2022

Researchers present [11C]JMJ-81 as a new PET tracer for brain PDE4D quantification

April 4, 2022

AZD-9574: a selective PARP1 inhibitor suitable for cancer treatment

April 4, 2022

AC-0027136 improves memory impairment and mitochondrial function

March 31, 2022

Sosei Heptares' GLP-1/2 agonist HTL-0030023 shows promising results for treating NAFLD and NASH

March 28, 2022

MK-6158: sGC stimulator clinical candidate for pulmonary arterial hypertension

March 28, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Coreterra Therapeutics patents agents for schizophrenia
BioWorld Science
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.